Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02652468 · ClinicalTrials.gov registry record · NA

TCR-α/β and CD19 Depleted Stem Cell Grafts From Haplo Donors for HSCT in Relapsed Lymphoma

A NA study of Lymphoma, sponsored by University of Wisconsin, Madison.

Completed
Registry status
NA
Development phase
11
Enrollment target
1
Study location

NCT02652468: Completed NA study of Lymphoma, sponsored by University of Wisconsin, Madison.

NCT02652468 is a NA study of Lymphoma that has completed, run by University of Wisconsin, Madison. The registered enrollment target is 11 participants, below the 484-participant average among 299 other Lymphoma trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02652468, a NA study of Lymphoma, has completed, sponsored by University of Wisconsin, Madison.

COMPLETED
Registry status
NA
Development phase
11 participants
Enrollment target
1
Study location

Study Summary

To determine engraftment of neutrophils and platelets at 28 days following alpha/beta T-cell and CD19 cell depletion using Human Leukocyte Antigen (HLA) haploidentical donors for peripheral blood stem cell transplant in relapsed lymphoma. Assess incidence of acute Graft Versus Host Disease (GVHD), chronic GVHD, graft failure rate, treatment related mortality rate, progression free survival and overall survival of patients. The stem cell product will be processed using an investigational Miltenyi cell selection device/system that removes the alpha/beta T-cells and CD19+ cells, immune system cells that are more likely to cause GVHD.

Primary Outcome

To determine engraftment of neutrophils and platelets at 28 days following alpha/beta T-cell depletion using Human Leukocyte Antigen (HLA) haploidentical donors for stem cell transplant in relapsed lymphoma.

Conditions Studied

Interventions

  • DRUG Cyclophosphamide
  • DRUG Mesna
  • DRUG Fludarabine Phosphate
  • RADIATION Total nodal irradiation
  • BIOLOGICAL T Cell-Depleted Hematopoietic Stem Cell Transplantation

Study Locations (1)

Wisconsin

  • University of Wisconsin Carbone Cancer Center - Madison

Trial Details

FieldValue
Enrollment Target 11 participants
Start Date 2016-03-10
Est. Completion 2021-09-17
Phase NA
University of Wisconsin, Madison

1,039 total trials

What the finished NCT02652468 record still lists

NCT02652468 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 11 participants, a relatively small participant target, below the 484-participant average among 299 other Lymphoma trials with a reported enrollment target (98% lower).

The record links to 1 condition, with Lymphoma appearing as the primary indexed condition, and to 5 interventions - of which Cyclophosphamide is the first listed.

NCT02652468 reports a single indexed study location in Wisconsin.

Frequently Asked Questions

What is clinical trial NCT02652468 about?

NCT02652468 is a clinical study titled "TCR-α/β and CD19 Depleted Stem Cell Grafts From Haplo Donors for HSCT in Relapsed Lymphoma". To determine engraftment of neutrophils and platelets at 28 days following alpha/beta T-cell and CD19 cell depletion using Human Leukocyte Antigen (HLA) haploidentical donors for peripheral blood stem cell transplant in relapsed lymphoma. Assess incidence of acute Graft Versus Host Disease (GVHD), ...

What is the current status of trial NCT02652468?

This trial is currently completed. It is a NA study. The enrollment target is 11 participants. The study started on 2016-03-10. Estimated completion is 2021-09-17.

What conditions does trial NCT02652468 study?

This clinical trial studies the following conditions: Lymphoma.

What interventions are being tested in trial NCT02652468?

The interventions under investigation include: Cyclophosphamide (DRUG), Mesna (DRUG), Fludarabine Phosphate (DRUG), Total nodal irradiation (RADIATION), T Cell-Depleted Hematopoietic Stem Cell Transplantation (BIOLOGICAL).

Who is sponsoring clinical trial NCT02652468?

This trial is sponsored by University of Wisconsin, Madison, which has 1,039 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02652468 being conducted?

This trial has 1 study location across Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Lymphoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT02652468's enrollment target sits among peer trials

11 273rd of 299 higher than 25 of 299 other Lymphoma trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Lymphoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03114462 · 11 participants · Phase 1

    Trial of Stereotactic HYpofractionateD RadioAblative (HYDRA) Treatment of Laryngeal Cancer

  • NCT06039709 · 11 participants · Phase 1

    Sonodynamic Therapy in Patients With Recurrent GBM

  • NCT06425380 · 11 participants · NA

    Pilot Open-Label Trial of Resistant Potato Starch in Patients With Cirrhosis and Overt Hepatic Encephalopathy

  • NCT06472661 · 11 participants · Early Phase 1

    FUSA With Intratumoral PolyICLC in Regionally Advanced Resectable Melanoma

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT02652468, the US trial registry maintained by the National Library of Medicine. NCT02652468 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.